Morningstar Lab
MorningStar Laboratories, LLC (“MSL” or “the Company”), a leading developer of precision diagnostic tests that address unmet clinical needs, proudly announces its SmartVascular Dx™ (SVDx) test (formally known as the PULS Cardiac test), designed to transform the early detection and management of vascular health, empowering healthcare providers to implement proactive strategies that significantly enhance patient outcomes.Vascular disease continues to be a leading cause of morbidity and mortality worldwide. The SVDx test leverages state-of-the-art technology to provide comprehensive insights into a patient’s vascular health, allowing for earlier intervention and a more personalized care plan. By identifying at-risk individuals through advanced biomarkers, healthcare professionals can initiate preventative measures before critical health issues arise. For more information visit https://www.mslinc.com